Autoimmune disorders result from
an overactive immune response of a body working against its own cells.
The disease is broadly classified into two types: systemic autoimmune
diseases, which affect several organs of the body; and localized
autoimmune diseases, which affect only one organ. Around 80 autoimmune
diseases are recognized under these two categories. The disease affected
over 300 million people across the globe in 2009. No defined reasons
have been discovered to date for the occurrence of the disorder. Women
are more prone to autoimmune diseases, constituting 70%-75% of all
autoimmune patients.
The overall market for the treatment of autoimmune disorders is analyzed into the submarkets for applications, products, services, and technologies. The global market for autoimmune disease treatments is estimated to be at $37.84 billion in 2009, and is growing at a CAGR of 12.7% from 2009 to 2014 to reach an estimated $68.81 billion in 2014. The effects of the global meltdown are given careful consideration when forecasting the market.
The application market is further classified into the treatment markets for systemic autoimmune diseases and localized autoimmune diseases. The applications market is dominated mostly by rheumatoid arthritis under the systemic disease segment, while multiple sclerosis is the major application market under the localized disease segment. These two disorders account for 75% of the total applications market. The other major diseases analysed under the application market are psoriasis, lupus, type I diabetes, inflammatory bowel disease, and thyroid disorders, which together account for 15%-20% of the global applications market.
The product market is classified on the basis of the drugs, diagnostic equipments, therapeutic and monitoring equipment. Drugs form the largest segment of the products market, with major drugs such as NSAID, DMARD, biologic DMARD, Avonex, Rebif, Copaxone, Betaseron, and 5-ASA. The services market consists of consultation and diagnosis, therapy and monitoring, and drug development. The wide and increasing prevalence of autoimmune diseases is boosting the drugs market along with the therapy and monitoring market; along with the fact that almost all autoimmune diseases are chronic and have no permanent cure.
The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014.
Each segment is analyzed and forecasts are for four geographical regions – North America, Europe, Asia Pacific, and Rest of World (ROW). The North American market includes U.S. and Canada. The European market includes Germany, France, U.K. and other countries in European continent. The major Asia Pacific markets include Japan, Australia, China, India, Singapore and Malaysia. Mexico has been considered in the ROW category along with Middle East, Russia and South Africa.
North America is the largest market for autoimmune treatment with a 42% share of the global market, followed by Europe with a 30% share. However, Asia Pacific with a 20% market share is the fastest-growing market with a 13.3% CAGR from 2009 to 2014
The overall market for the treatment of autoimmune disorders is analyzed into the submarkets for applications, products, services, and technologies. The global market for autoimmune disease treatments is estimated to be at $37.84 billion in 2009, and is growing at a CAGR of 12.7% from 2009 to 2014 to reach an estimated $68.81 billion in 2014. The effects of the global meltdown are given careful consideration when forecasting the market.
The application market is further classified into the treatment markets for systemic autoimmune diseases and localized autoimmune diseases. The applications market is dominated mostly by rheumatoid arthritis under the systemic disease segment, while multiple sclerosis is the major application market under the localized disease segment. These two disorders account for 75% of the total applications market. The other major diseases analysed under the application market are psoriasis, lupus, type I diabetes, inflammatory bowel disease, and thyroid disorders, which together account for 15%-20% of the global applications market.
The product market is classified on the basis of the drugs, diagnostic equipments, therapeutic and monitoring equipment. Drugs form the largest segment of the products market, with major drugs such as NSAID, DMARD, biologic DMARD, Avonex, Rebif, Copaxone, Betaseron, and 5-ASA. The services market consists of consultation and diagnosis, therapy and monitoring, and drug development. The wide and increasing prevalence of autoimmune diseases is boosting the drugs market along with the therapy and monitoring market; along with the fact that almost all autoimmune diseases are chronic and have no permanent cure.
The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014.
Each segment is analyzed and forecasts are for four geographical regions – North America, Europe, Asia Pacific, and Rest of World (ROW). The North American market includes U.S. and Canada. The European market includes Germany, France, U.K. and other countries in European continent. The major Asia Pacific markets include Japan, Australia, China, India, Singapore and Malaysia. Mexico has been considered in the ROW category along with Middle East, Russia and South Africa.
North America is the largest market for autoimmune treatment with a 42% share of the global market, followed by Europe with a 30% share. However, Asia Pacific with a 20% market share is the fastest-growing market with a 13.3% CAGR from 2009 to 2014
